Spire Wealth Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Spire Wealth Management’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-500	Closed	-$1K	–	2335
2022 Q3	$1K	Hold	500	–	–	﹤0.01%	2065
2022 Q2	$1K	Sell	500 -350	-41%	-$1.07K	﹤0.01%	2491
2022 Q1	$3K	Hold	850	–	–	﹤0.01%	2322
2021 Q4	$4K	Hold	850	–	–	﹤0.01%	2620
2021 Q3	$5K	Hold	850	–	–	﹤0.01%	2271
2021 Q2	$7K	Buy	850 +500	+143%	+$4.72K	﹤0.01%	2222
2021 Q1	$4K	Buy	+350	New	+$5.28K	﹤0.01%	2683

Other funds holding ELDN

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

JMAC Enterprises Newtown, Pennsylvania $593M AUM 22.22% 1-Year Est. Return

Spire Wealth Management's ELDN Position: Q4 2022 in Review

Spire Wealth Management sold out of Eledon Pharmaceuticals (ELDN) in Q4 2022, closing a stake of 500 shares — an estimated $1K sold.

Spire Wealth Management first reported a position in ELDN in Q1 2021 and held it in 7 quarters. The position peaked at $7K in Q2 2021. 28 funds tracked by Wall St. Rank hold ELDN as of Q4 2022.

Spire Wealth Management reported no remaining Eledon Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Spire Wealth Management sold 500 Eledon Pharmaceuticals shares in Q4 2022, an estimated $1K.
Spire Wealth Management first reported a position in Eledon Pharmaceuticals in Q1 2021 and held it in 7 quarters.
Spire Wealth Management's Eledon Pharmaceuticals position peaked at $7K in Q2 2021.
28 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2022.

Based on Spire Wealth Management's 13F filing for Q4 2022, filed 3 Feb 2023.